Kevin M Takakuwa1, Jeffrey Y Hergenrather1, Frances S Shofer2, Raquel M Schears3. 1. Society of Cannabis Clinicians, Sebastopol, California. 2. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Emergency Medicine, University of Central Florida, Orlando, Florida.
Abstract
Objective: To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design: Retrospective cohort study. Setting: A single-center cannabis medical practice site in California. Patients: A total of 180 patients who had a chief complaint of low back pain were identified (International Classification of Diseases, 10th Revision, code M54.5). Sixty-one patients who used prescription opioids were analyzed. Interventions: Cannabis recommendations were provided to patients as a way to mitigate their low back pain. Outcome Measures: Number of patients who stopped opioids and change in morphine equivalents. Results: There were no between-group differences based on demographic, experiential, or attitudinal variables. We found that 50.8% were able to stop all opioid usage, which took a median of 6.4 years (IQR=1.75-11 years) after excluding two patients who transitioned off opioids by utilizing opioid agonists. For those 29 patients (47.5%) who did not stop opioids, 9 (31%) were able to reduce opioid use, 3 (10%) held the same baseline, and 17 (59%) increased their usage. Forty-eight percent of patients subjectively felt like cannabis helped them mitigate their opioid intake but this sentiment did not predict who actually stopped opioid usage. There were no variables that predicted who stopped opioids, except that those who used higher doses of cannabis were more likely to stop, which suggests that some patients might be able to stop opioids by using cannabis, particularly those who are dosed at higher levels. Conclusions: In this long-term observational study, cannabis use worked as an alternative to prescription opioids in just over half of patients with low back pain and as an adjunct to diminish use in some chronic opioid users. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Objective: To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design: Retrospective cohort study. Setting: A single-center cannabis medical practice site in California. Patients: A total of 180 patients who had a chief complaint of low back pain were identified (International Classification of Diseases, 10th Revision, code M54.5). Sixty-one patients who used prescription opioids were analyzed. Interventions: Cannabis recommendations were provided to patients as a way to mitigate their low back pain. Outcome Measures: Number of patients who stopped opioids and change in morphine equivalents. Results: There were no between-group differences based on demographic, experiential, or attitudinal variables. We found that 50.8% were able to stop all opioid usage, which took a median of 6.4 years (IQR=1.75-11 years) after excluding two patients who transitioned off opioids by utilizing opioid agonists. For those 29 patients (47.5%) who did not stop opioids, 9 (31%) were able to reduce opioid use, 3 (10%) held the same baseline, and 17 (59%) increased their usage. Forty-eight percent of patients subjectively felt like cannabis helped them mitigate their opioid intake but this sentiment did not predict who actually stopped opioid usage. There were no variables that predicted who stopped opioids, except that those who used higher doses of cannabis were more likely to stop, which suggests that some patients might be able to stop opioids by using cannabis, particularly those who are dosed at higher levels. Conclusions: In this long-term observational study, cannabis use worked as an alternative to prescription opioids in just over half of patients with low back pain and as an adjunct to diminish use in some chronic opioid users. Copyright 2020, Mary Ann Liebert, Inc., publishers.
Entities:
Keywords:
chronic pain; low back pain; marijuana; medical cannabis; opiate abuse; prescription opioid use
Authors: Jasmina I Ivanova; Howard G Birnbaum; Matt Schiller; Evan Kantor; Bryan M Johnstone; Ralph W Swindle Journal: Spine J Date: 2011-05-20 Impact factor: 4.166
Authors: Erin E Krebs; Amy Gravely; Sean Nugent; Agnes C Jensen; Beth DeRonne; Elizabeth S Goldsmith; Kurt Kroenke; Matthew J Bair; Siamak Noorbaloochi Journal: JAMA Date: 2018-03-06 Impact factor: 56.272
Authors: Suzanne Nielsen; Pamela Sabioni; Jose M Trigo; Mark A Ware; Brigid D Betz-Stablein; Bridin Murnion; Nicholas Lintzeris; Kok Eng Khor; Michael Farrell; Andrew Smith; Bernard Le Foll Journal: Neuropsychopharmacology Date: 2017-03-22 Impact factor: 7.853
Authors: Staci A Gruber; Kelly A Sagar; Mary K Dahlgren; Megan T Racine; Rosemary T Smith; Scott E Lukas Journal: Front Pharmacol Date: 2016-10-13 Impact factor: 5.810
Authors: Cerina Lee; Mu Lin; Karen J B Martins; Jason R B Dyck; Scott Klarenbach; Lawrence Richer; Ed Jess; John G Hanlon; Elaine Hyshka; Dean T Eurich Journal: BMC Public Health Date: 2021-05-01 Impact factor: 3.295
Authors: Maja Kalaba; Laura MacNair; Erica N Peters; Graham M L Eglit; Lucile Rapin; Cynthia El Hage; Erin Prosk; Mark A Ware Journal: Cannabis Cannabinoid Res Date: 2021-05-10
Authors: Atefeh Noori; Anna Miroshnychenko; Yaadwinder Shergill; Vahid Ashoorion; Yasir Rehman; Rachel J Couban; D Norman Buckley; Lehana Thabane; Mohit Bhandari; Gordon H Guyatt; Thomas Agoritsas; Jason W Busse Journal: BMJ Open Date: 2021-07-28 Impact factor: 2.692